Varex Imaging Earnings Call Transcripts
Fiscal Year 2026
-
X-ray imaging markets remain stable, with strong OEM relationships and growth in both medical and industrial segments. New factories in India and innovative photon counting technology are set to drive future revenue, while recent refinancing has improved financial flexibility.
-
Business remains resilient amid geopolitical and tariff changes, with stable healthcare and industrial demand. China’s market has normalized, India facilities are ramping up for FY 2026-2028 growth, and photon counting technology is set to drive future margin expansion.
-
The meeting introduced board members, confirmed a quorum, and covered three proposals: board elections, executive compensation, and auditor ratification. All proposals passed, and stockholders could submit questions for live or later response.
-
Q1 FY2026 revenue rose 5% year-over-year to $210 million, led by 17% growth in the industrial segment and stable medical performance. Non-GAAP EPS doubled to $0.19, and strong customer engagement and innovation are fueling a robust pipeline. Guidance for Q2 projects continued growth.
-
Management highlighted strong positions in medical and industrial X-ray markets, with growth driven by new products, India manufacturing, and photon-counting technology. Tariffs and past challenges have been addressed, and major investments are expected to yield significant revenue gains in cargo, Rad, and CT detector segments over the next few years.
Fiscal Year 2025
-
Fourth quarter revenue grew 11% year-over-year, led by record Industrial sales and strong Medical demand. Full-year revenue rose 4%, with margin expansion and robust cash flow, despite tariff headwinds and a non-cash goodwill impairment. Gradual growth is expected in 2026.
-
Medical and industrial segments are both positioned for growth, with China and new cargo systems driving demand. Tariff mitigation strategies and new India factories are enhancing supply chain resilience. Innovation in photon counting and nanotube technologies is progressing, while financial health is improving through debt reduction and cash generation.
-
Third quarter revenue and gross margin exceeded guidance, driven by strong industrial demand and stable China sales after tariff relief. Non-GAAP EPS rose year-over-year, while a non-cash goodwill impairment led to a GAAP net loss. Q4 guidance anticipates growth in both segments.
-
Leads in X-ray imaging components, with strong medical and industrial presence and a focus on innovation. Recent results exceeded expectations, with normalized inventory and robust demand. Tariff mitigation includes supply chain diversification and new India plants, supporting growth in both medical and industrial markets.
-
Revenue grew 3% year-over-year to $213 million, with gross margin at 36% and strong cash flow. Tariffs are expected to reduce Q3 China sales by $20 million, but mitigation strategies and local manufacturing are underway. Guidance anticipates lower Q3 revenue and EPS.
-
Gradual recovery in China and normalized OEM inventories are supporting improved order rates. Strategic investments in India, photon counting, and cargo inspection are expected to drive significant growth, while supply chain diversification and financial discipline mitigate tariff and debt risks.
-
China demand is improving with gradual recovery, while supply chain diversification and local manufacturing have increased resilience to tariffs. Growth in photon counting and cargo inspection is expected to drive margin improvement and sales expansion by FY2026–2027.
-
Q1 FY25 revenue grew 5% year-over-year, with strong gross margin and cash generation. Medical and industrial segments both saw growth, especially in CT tubes and cargo inspection, while China sales improved. Guidance for Q2 anticipates continued revenue growth and stable margins.
-
A leading X-ray component manufacturer highlighted innovation in photon-counting detectors, expansion into cargo inspection, and new manufacturing in India as key growth drivers. Recurring revenue streams and long-term customer relationships support stability, while recent headwinds from China and inventory normalization are subsiding.
Fiscal Year 2024
-
Q4 revenue reached $206 million, down 10% year-over-year, with medical and industrial segments both declining. Gross margin was 33%, and non-GAAP EPS exceeded guidance. Destocking is expected to subside by Q2 2025, while China sales remain stable but subdued.
-
Q3 revenue fell 10% year-over-year, with medical segment down and industrial up, driven by strong cargo sales. Gross margin and EPS declined, impacted by product mix and China softness. Guidance for Q4 remains cautious, with gradual improvement expected in 2025 as inventory pressures ease.
-
The company is optimistic about 2025, expecting recovery in China, completion of inventory normalization, and growth from photon counting technology. Financial flexibility is strong, with plans to reduce debt, while risks include US-China trade policy shifts.
-
Revised summary: The company faces short-term challenges in its medical segment from China’s anti-corruption campaign and inventory shifts, while its industrial segment, especially cargo inspection, remains strong. Key R&D areas are photon counting detectors and nanotube tech, with growth expected in photon counting. The company is focused on deleveraging and liquidity.